News

As per the terms of the licensing deal, Allergan will fund phase 3 development of tavilermide. Mimetogen will receive an upfront payment of $50m from Allergan. The deal

Under terms of the agreement, GenomOncology’s GO Clinical Workbench™ will now support interpretation of multiple ArcherDX assays, including ALK, RET, ROS1, Solid Tumor, and Comprehensive Thyroid and Lung

The objective is to develop an original and non-invasive therapeutic medical device for children with ADHD. Developed in close collaboration with neuroscientists and clinicians, the personalized medical solution

Under the double-blind, placebo-controlled, parallel-group study, about 120 patients will be randomized to receive once-daily VK5211 doses of 0.5 mg, 1.0 mg or 2.0 mg or placebo for

The company enrolled the first patients in the study of BI 1482694 (HM61713) in patients with non-small cell lung cancer (NSCLC) whose tumours test positive for the T790M

The approval is subject to Mylan’s divestiture of several products after the consummation of the offer. Mylan is offering $75 in cash and 2.3 ordinary shares for each

The companies have started a phase I clinical trial to evaluate GSK’s investigational GSK3174998 as monotherapy in combination with Merck’s Keytruda (pembrolizumab) in patients with tumors that have

The acquisition was completed by means of a short-form merger under the Delaware law. Post the short-form merger, InSite Vision has become an indirect wholly-owned subsidiary of Sun

The companies will develop joint protocols that explore potential synergistic effects of their respective drug candidates, as well as potential new drug candidate opportunities. "After recent discussions with